Novartis AG (SWX:NOVN)

Switzerland · Delayed Price · Currency is CHF

123.10

-1.90 (-1.52%)

Jul 20, 2026, 5:31 PM CET

33.38% (1Y)

Market Cap	225.34B +20.9%
Revenue (ttm)	45.38B +6.3%
Net Income	10.86B +5.2%
EPS	5.60 +9.5%
Shares Out	1.83B
PE Ratio	21.98
Forward PE	16.94
Dividend	3.70 (3.01%)
Ex-Dividend Date	Mar 10, 2026

Volume	1,700,114
Open	123.50
Previous Close	125.00
Day's Range	123.02 - 124.56
52-Week Range	91.20 - 131.00
Beta	0.50
Analysts	Hold
Price Target	123.72 (+0.2%)
Earnings Date	Jul 21, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1996

Employees 75,267

Stock Exchange SIX Swiss Exchange

Ticker Symbol NOVN

Full Company Profile

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 22 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 123.72, which is an increase of 0.20% from the latest price.

Price Target

CHF 123.72

(0.20% upside)

Analyst Consensus: Hold

Stock Forecasts